Dementia alarm bells in Boroondara

FORMER librarian Heather Robertson-Clarke can no longer read or write and is slowly losing her speech.

The Hawthorn East resident knows first-hand the effects of dementia after being diagnosed with the cruel and debilitating disease three years ago.

She is just one of thousands across Boroondara suffering from the affliction.

And the number of Boroondara residents with dementia is expected to skyrocket 170 per cent by 2050, a new study has revealed.

The figures, commissioned by Alzheimers Australia Vic, projected Boroondara residents living with dementia will balloon from 2582 today to more than 6900 in less than 40 years, placing a heavy toll on the districts medical and care services.

Alzheimers Australia Vic chief executive Maree McCabe said the prevalence of dementia would cost the nation $83 billion a year by 2050, which will exceed any other medical condition.

(The figures) really are frightening - its really important we are proactive, Ms McCabe said.

Almost 72,000 Victorians have dementia, which is expected to boom to 246,000 by 2050, according to the study by Deloitte Access Economics.

Prof David Ames, director of Parkvilles National Ageing Research Institute, said statistics revealed there would be as many Victorians with dementia in 2050 as there are Australians presently with the condition.

Ms McCabe said early detection was key.

Read more:
Dementia alarm bells in Boroondara

More dementia treatment available in Ashburton

Hon Jo Goodhew

Associate Minister of Health

26 April 2012 Media Statement More dementia treatment available in Ashburton

More local Mid Canterbury people suffering from dementia will be cared for in their local community following an extension and refurbishment to an aged care hospital unit officially opened today by Associate Health Minister Jo Goodhew.

This community investment adds another 10 bed dementia unit to the existing 12 psychogeriatric and 15 long stay hospital beds already in the Tuarangi resthome and hospital, says Mrs Goodhew.

We are living longer and sadly that also means that the number of older New Zealanders with dementia is increasing.

A loved one living with dementia is a challenge faced by many families, but there is much that we can do. These additional dedicated beds mean that local people with dementia can, if they choose, remain closer to home should they need residential care.

Providing care for individuals with dementia is a growing issue for our country. The 2010 aged residential care services review identified the most pressing need as expanding dementia units, beds and services.

The Government responded last year with an additional $44 million over four years to look after people living with dementia. This includes $40 million for residential dementia services and $4 million for respite care for full-time carers of individuals with dementia.

The Government is committed to ensuring all older people in residential care, including those with dementia, receive quality services and care.

Read the original here:
More dementia treatment available in Ashburton

MULTIMEDIA SPECIAL: Don't forget Yarra Ranges dementia sufferers

>> MULTIMEDIA SPECIAL: Love amid loss as dementia takes hold

FRIGHTENING new statistics reveal the number of residents in the Yarra Ranges with dementia is expected to skyrocket by 298 per cent by 2050.

The figures, commissioned by Alzheimers Australia Vic, project the number of Yarra Ranges residents living with dementia will grow from 1543 to more than 6000 in less than 40 years, placing a heavy toll on the districts medical and care services.

The shock figures come as Caladenia Dementia Care in Mooroolbark campaigns for $1.7 million funding to build a dementia-specific overnight respite centre.

Manager Sarah Yeates said there was an enormous and growing need for the centre.

The care that happens in nursing homes is just not suitable for people with dementia, especially for those in the early stages, Ms Yeates said.

She said they were seeing an increasing demand for their services particularly from younger people, with their youngest patient just 34.

The community has already raised $85,000 for the project, but Ms Yeates said they were continuing to appeal for funding from state and federal governments.

Among those who will benefit from respite care is Coldstreams Gerda and Marty De Clercq (pictured).

Two-and-a-half years ago Mr De Clercq, 68, was diagnosed with dementia and his wife is his sole carer.

Go here to read the rest:
MULTIMEDIA SPECIAL: Don't forget Yarra Ranges dementia sufferers

MULTIMEDIA SPECIAL: Don’t forget Yarra Ranges dementia sufferers

>> MULTIMEDIA SPECIAL: Love amid loss as dementia takes hold

FRIGHTENING new statistics reveal the number of residents in the Yarra Ranges with dementia is expected to skyrocket by 298 per cent by 2050.

The figures, commissioned by Alzheimers Australia Vic, project the number of Yarra Ranges residents living with dementia will grow from 1543 to more than 6000 in less than 40 years, placing a heavy toll on the districts medical and care services.

The shock figures come as Caladenia Dementia Care in Mooroolbark campaigns for $1.7 million funding to build a dementia-specific overnight respite centre.

Manager Sarah Yeates said there was an enormous and growing need for the centre.

The care that happens in nursing homes is just not suitable for people with dementia, especially for those in the early stages, Ms Yeates said.

She said they were seeing an increasing demand for their services particularly from younger people, with their youngest patient just 34.

The community has already raised $85,000 for the project, but Ms Yeates said they were continuing to appeal for funding from state and federal governments.

Among those who will benefit from respite care is Coldstreams Gerda and Marty De Clercq (pictured).

Two-and-a-half years ago Mr De Clercq, 68, was diagnosed with dementia and his wife is his sole carer.

Go here to read the rest:
MULTIMEDIA SPECIAL: Don't forget Yarra Ranges dementia sufferers

Bakewells and dogs vs dementia

26 April 2012 Last updated at 02:44 ET By James Gallagher Health and science reporter, BBC News

The drifting smells of a Bakewell tart, guide dogs for the mind and hi-tech wristbands could all have a future in helping people with dementia.

They are some of the winners of a competition by the Design Council and the Department of Health to develop new ideas in care.

The winners are all prototypes, but the aim is to produce them on a mass scale.

David Cameron has described dementia as a "national crisis" which affects 800,000 people in the UK.

The slow death of the brain in dementia affects memory, language and understanding. One of the problems can be forgetting to eat, which is what one of the design ideas is trying to overcome.

The "Ode" project works on the same principle as smells wafting from the kitchen making you hungry. It pumps fragrances of food into the air to whet the appetite of people who are not eating.

Lizzie Olstrom, who is part of the design team, told the BBC: "So much of appetite is about smell, the sensory anticipation of food. [Ode] uses fragrances to re-awaken appetite."

So far they have used smells of a Bakewell tart, citrus and spices. However, the tempting aroma of fish and chips has not translated so well. "Would you want vinegar and wet paper smells in the house?" she asked.

So far, she said the product had "compelling results" after being tested in homes. However, larger-scale tests will be needed to see if the product really helps people.

See the rest here:
Bakewells and dogs vs dementia

Dementia " the most serious health crisis this century"

Alzheimers New Zealand urges New Zealand government to recognise dementia as the most serious health crisis to be faced this century

Alzheimers New Zealand is encouraged by the Australian federal governments recent announcement that they will be committing almost AUS $270 million to dementia and hopes this announcement will go some way toward influencing our own government to take further financial action in New Zealand.

Under an aged-care reform package the Australian government will spend a total of $269.4 million over five years, including $164.3 million to be paid as supplements to people with dementia living in aged-care facilities and at home. The remainder of the money will go toward promoting early diagnosis of the disease. However, this amount this falls short of calls by Alzheimer's Australia for a $500m investment.

This financial commitment from the Australian government coupled with the recent announcement from the UK government that they will be doubling funding for dementia research, shows how other governments are stepping up and taking action to prepare for the inevitable rise in dementia. Alzheimers New Zealand is now urging our own government to take action and recognise dementia as the most serious health crisis to be faced this century.

A report released this month by the World Health Organisation (WHO) revealed the incidence of dementia is exploding in line with the rapid growth in aging populations worldwide, the most profound socio-economic phenomenon of this century. The number of people living with dementia worldwide, estimated at 35.6 million in 2010, is set to nearly double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050.

In New Zealand, dementia is expected to increase to epidemic proportions in the very near future due to our countrys aging population. Today there around 44,000 recorded cases of dementia, however, we expect the true figure to be significantly higher than this as only 60% of people are diagnosed, according to the World Alzheimer Report 2011. Around half of all New Zealanders with dementia live with family carers, many of whom are providing around-the-clock care with little or no government support.

Alzheimers New Zealand is now approaching the third year of its National Dementia Strategy, launched at Parliament in May 2010. The strategy establishes clear actions to better support people with dementia and their carers. The document was developed in consultation with stakeholders throughout the sector, as well as with those who face the daily challenge of living with the disease. The strategy identifies key areas needing investment including early diagnosis and management of the disease, appropriate quality services, better supports for carers who provide in-home care, and development of a skilled work-force.

The success of the National Dementia Strategy hinges on the New Zealand governments recognition of the social and economic impacts of the disease and adopting dementia as a national health priority. While the New Zealand dementia community is working towards fulfilling the action points of the strategy, the New Zealand government is yet to formally adopt it.

The New Zealand government needs to recognise dementia as a national crisis in order to adequately fund the sector and best prepare for the significant costs of dementia in the future.

Last years Budget announcement of $44m to dementia was a step in the right direction but additional funding is needed to support people living with dementia in the home, says Alzheimers New Zealand chairperson, Martin Brooks.

The rest is here:
Dementia " the most serious health crisis this century"

Dementia ” the most serious health crisis this century”

Alzheimers New Zealand urges New Zealand government to recognise dementia as the most serious health crisis to be faced this century

Alzheimers New Zealand is encouraged by the Australian federal governments recent announcement that they will be committing almost AUS $270 million to dementia and hopes this announcement will go some way toward influencing our own government to take further financial action in New Zealand.

Under an aged-care reform package the Australian government will spend a total of $269.4 million over five years, including $164.3 million to be paid as supplements to people with dementia living in aged-care facilities and at home. The remainder of the money will go toward promoting early diagnosis of the disease. However, this amount this falls short of calls by Alzheimer's Australia for a $500m investment.

This financial commitment from the Australian government coupled with the recent announcement from the UK government that they will be doubling funding for dementia research, shows how other governments are stepping up and taking action to prepare for the inevitable rise in dementia. Alzheimers New Zealand is now urging our own government to take action and recognise dementia as the most serious health crisis to be faced this century.

A report released this month by the World Health Organisation (WHO) revealed the incidence of dementia is exploding in line with the rapid growth in aging populations worldwide, the most profound socio-economic phenomenon of this century. The number of people living with dementia worldwide, estimated at 35.6 million in 2010, is set to nearly double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050.

In New Zealand, dementia is expected to increase to epidemic proportions in the very near future due to our countrys aging population. Today there around 44,000 recorded cases of dementia, however, we expect the true figure to be significantly higher than this as only 60% of people are diagnosed, according to the World Alzheimer Report 2011. Around half of all New Zealanders with dementia live with family carers, many of whom are providing around-the-clock care with little or no government support.

Alzheimers New Zealand is now approaching the third year of its National Dementia Strategy, launched at Parliament in May 2010. The strategy establishes clear actions to better support people with dementia and their carers. The document was developed in consultation with stakeholders throughout the sector, as well as with those who face the daily challenge of living with the disease. The strategy identifies key areas needing investment including early diagnosis and management of the disease, appropriate quality services, better supports for carers who provide in-home care, and development of a skilled work-force.

The success of the National Dementia Strategy hinges on the New Zealand governments recognition of the social and economic impacts of the disease and adopting dementia as a national health priority. While the New Zealand dementia community is working towards fulfilling the action points of the strategy, the New Zealand government is yet to formally adopt it.

The New Zealand government needs to recognise dementia as a national crisis in order to adequately fund the sector and best prepare for the significant costs of dementia in the future.

Last years Budget announcement of $44m to dementia was a step in the right direction but additional funding is needed to support people living with dementia in the home, says Alzheimers New Zealand chairperson, Martin Brooks.

The rest is here:
Dementia " the most serious health crisis this century"

DEMENTIA CARE: the cost of caring in the west

DEMENTIA will become Australias most expensive medical condition over the next 40 years, with annual costs predicted to balloon from $6 billion this year to about $83 billion by 2050.

Alzheimers Australia Vic chief executive Maree McCabe said aged care for a dementia patient cost about $21,500 each year and would increase exponentially with wages, treatment and interventions.

Governments know what we need, the time has come now to outline a funding plan for it - not for the next year or five years, but for over the next decade to 20 years, Ms McCabe said.

The Federal Government terminated The Dementia Initiative - making dementia a national health priority in its 2011-12 Budget.

Last week, the Federal Government announced $268.4 million over five years to tackle dementia.

This includes $164.3 million for people receiving home care packages and in residential care, and there will also be extra support for primary health care providers.

However this falls short of the $500 million over five years called for by Alzheimers Australia.

We need to increase our services, Ms McCabe said.

We need to raise awareness about dementia, especially when it comes to ensuring people achieve a timely diagnosis.

National Ageing Research Institute director Prof David Ames said huge advances had been made in understanding the biology of dementia, but treatments remained limited.

Here is the original post:
DEMENTIA CARE: the cost of caring in the west

Man arrested or planting mercury at Albany Med faces federal charges

Martin Kimber

ALBANY The man already charged with putting mercury in food and on other places including the heater where it would be vaporized and inhaled in the Albany Medical Center Hospital cafeteria now faces federal charges.

U.S. Attorney Richard Hartunian said Martin S. Kimber, 58, of Ruby, faces charges of illegal disposal of a hazardous waste in a manner posing a danger of death of serious bodily injury to others, a charge more commonly referred to as knowing endangerment, and illegal storage and disposal of a hazardous waste without a permit.

The retired pharmacist was previously arrested by Albany Police, with help from FBI and Department of Health investigators, for tampering with a consumer product in the first degree.

According to the U.S. Attorneys Office, a search of Kimbers Ulster County home found he had 21 guns and literature reflecting a sympathy for domestic terrorism.

The cover page in one book, The Turner Diaries includes the phrase This book contains racist propaganda and The FBI said it was a blueprint for the Oklahoma City Bombing.

Investigators also discovered a Nazi swastika on the wall.

The knowing endangerment charge carries a 15 year maximum jail time and a fine of $250,000 or twice the gross loss to any victim. The storage and disposal of hazardous waste without a permit can lead to a maximum of five years in jail and a fine of $250,000 or twice the gross loss to any victim.

The mercury was found in some of the food in the cafeteria that was eaten by at least one person. That person was treated at the hospitals emergency room.

Follow this link:
Man arrested or planting mercury at Albany Med faces federal charges

Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the …

ATLANTA, April 26, 2012 /PRNewswire/ -- UCB today announced interim results from the VITOBA (VImpaT added to One Baseline AED) study, which showed that patients with less refractory partial-onset seizures treated withVimpat (lacosamide) C-V as add-on to monotherapy experienced seizure reduction. These data were presented today at the 64th annual meeting of the American Academy of Neurology (AAN) in New Orleans.

VITOBA is a six-month prospective, non-interventional study of the efficacy, safety and tolerability of lacosamide when added to a single AED in patients with partial-onset seizures. The study has a planned enrollment of 500 adult patients. This interim analysis included efficacy data for 99 patients and safety data for 109 patients.

The patient population in VITOBA reflects epilepsy patients treated in routine clinical practice. The majority of patients (73.4 percent) had received only 1-3 AEDs since diagnosis. The mean lacosamide maintenance dose was 250mg/day and the median was 200mg/day.

Compared to the overall VITOBA study population, patients treated with only one lifetime AED experienced the greatest benefit from add-on therapy with lacosamide:

Treatment emergent adverse events (TEAEs) included fatigue (11.9 percent), dizziness (10.1 percent) and convulsion (5.5 percent).

"While preliminary, this interim analysis is noteworthy because it reflects a real-world treatment setting and suggests the effect of adding Vimpat as an adjunctive therapy after initial monotherapy. These results need to be confirmed by the final analysis when the study concludes," said Matthias Noack-Rink, lead study author and Medical Affairs Director, Epilepsy, UCB Germany.

Vimpat is indicated as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy. The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of lacosamide-treated patients, and greater than placebo, were dizziness, headache, nausea and diplopia. Additional important safety information for Vimpat is available at the end of the press release.

About EpilepsyEpilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and 3 million people in the U.S.Anyone can develop epilepsy; it occurs across all ages, races and genders. Uncontrolled seizures and medication side effects pose challenges to independent living, learning and employment, so the goal of epilepsy treatment is seizure freedom with minimal side effects. More than 1 million patients in the U.S. continue to have seizures despite initial therapy, and more than 800,000 patients in the U.S. continue to have seizures despite treatment with two or more therapies.[1],[2]

About VimpatVimpat tablets and injection were launched in the US in May 2009 as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are aged 17 years and older. Vimpat injection is a short-term replacement when oral administration is not feasible in these patients. Vimpat oral solution was launched in June 2010. The availability of the oral tablets, oral solution, and IV injection allows for consistent treatment in a hospital setting. The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat -treated patients, and greater than placebo, were dizziness, headache, nausea and diplopia. Additional important safety information for Vimpat is available at the end of the press release.

In the European Union, Vimpat (film-coated tablets and solution for infusion) is approved as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy, aged 16 years and older. Vimpat solution for infusion may be used when oral administration is temporarily not feasible.

View post:
Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the ...

Man charged with leaving mercury in Albany Med cafeteria now facing federal charges

Martin Kimber

ALBANY The man already charged with putting mercury in food and on other places including the heater where it would be vaporized and inhaled in the Albany Medical Center Hospital cafeteria now faces federal charges.

U.S. Attorney Richard Hartunian said Martin S. Kimber, 58, of Ruby, faces charges of illegal disposal of a hazardous waste in a manner posing a danger of death of serious bodily injury to others, a charge more commonly referred to as knowing endangerment, and illegal storage and disposal of a hazardous waste without a permit.

The retired pharmacist was previously arrested by Albany Police, with help from FBI and Department of Health investigators, for tampering with a consumer product in the first degree.

According to the U.S. Attorneys Office, a search of Kimbers Ulster County home found he had 21 guns and literature reflecting a sympathy for domestic terrorism.

The cover page in one book, The Turner Diaries includes the phrase This book contains racist propaganda and The FBI said it was a blueprint for the Oklahoma City Bombing.

Investigators also discovered a Nazi swastika on the wall.

The knowing endangerment charge carries a 15 year maximum jail time and a fine of $250,000 or twice the gross loss to any victim. The storage and disposal of hazardous waste without a permit can lead to a maximum of five years in jail and a fine of $250,000 or twice the gross loss to any victim.

The mercury was found in some of the food in the cafeteria that was eaten by at least one person. That person was treated at the hospitals emergency room.

Excerpt from:
Man charged with leaving mercury in Albany Med cafeteria now facing federal charges

Cypress resident crowned Little Miss Wheelchair Texas

With her sparkling tiara, polka-dotted dress and beaming smile, 8-year-old Alana Little, a second grade student at Moore Elementary School, looks every bit a princess, although her fairy tale cant be found in storybooks.

Alana or simply Lana, as she is known by her family and friends was crowned Little Miss Wheelchair Texas 2012 on March 24 at the Crowne Plaza in Houston, selected by the Miss Wheelchair Texas Foundation for her inspiring story.

That night at the gala, Lana got a very long standing ovation for her story, said Teri Little, Lanas maternal grandmother, who has helped raise the young girl since she was 16 months old. Lanas been through a lot. Shes a tough cookie, that one.

As the result of an extremely rare genetic disorder, worsened by the effects of drug and alcohol exposure in utero, Lana was diagnosed with ataxia-telangiectasia, or A-T, at 23 months. The disease combines the worst symptoms of muscular dystrophy, cerebral palsy, cystic fibrosis and immune deficiencies.

Those with A-T are 1,000 times more likely to get cancer. There are an estimated 500 children in the U.S. living with A-T today, but this number is too small for pharmaceutical companies to conduct research for a cure.

It attacks the cerebellum, and Lanas cerebellum has been destroyed by the disease already. If we were to let Lana walk, she would more than likely fall down immediately or wobble like shes drunk, Terri said.

Lana has relied on a wheelchair for part-time mobility since she was 2, primarily to cope with the excessive fatigue that sends her to bed by 5:30 p.m. each day. She made the transition to full-time wheelchair dependence this past summer.

As Little Miss Wheelchair Texas, Lana will make public appearances at Texas Childrens Hospital, MD Anderson and a special needs program with the National Dance Institute. Her year-long service will serve as a means to bring light to children living with paralyzing diseases like A-T.

We were just so happy for her and happy we were going to be able to educate more people about the disease, said Elizabeth Casey, Lanas aunt and part-time aide.

As part of her term with the crown, Lana and her family have started the I Can, Just Watch Me initiative, which seeks to spread an empowering message about the abilities, rather than the disabilities, of children with special needs. Children are photographed with a sign of the slogan, and the images are shared online along with the childs name, age and diagnosis.

More:
Cypress resident crowned Little Miss Wheelchair Texas

Multiple Sclerosis Patients Find Improvement in Walking with BalanceWear®

OAKLAND, Calif.--(BUSINESS WIRE)--

The first phase of the NIH study, Movement Ability Changes with Balance-Based Torso-Weighting (BBTW) in Multiple Sclerosis (MS), provided important results for Multiple Sclerosis patients suffering with balance and walking challenges. The study is funded by a National Institutes of Health Recovery Grant that was awarded to Samuel Merritt University (SMU) Physical Therapy Professor Dr. Gail Widener, PT, and Dr. Diane Allen at San Francisco State University to continue research into Balance-Based Torso Weighting (BBTW) and its effects on Multiple Sclerosis (MS) mobility challenges. The first phase of the study validates previous research funded by the National MS Society.

Physical Therapist, Cynthia Gibson-Horn, discovered that strategic application of small amounts of weight could counter-balance directional losses and dramatically improve stability in patients with MS, Parkinsons disease, stroke, TBI ataxia and other Sensory Based Motor Disorders (SBMD) during clinical applications. This discovery led to the development of the patented BBTW method, which has now helped hundreds of patients. The NIH funded research provides documented evidence of the efficacy of her clinical observations.

The first phase of the NIH study supplements other research into BBTW, the technology behind BalanceWear, which has been highly successful in improving mobility for patients with MS, says Steve Cookston, CEO of Motion Therapeutics, the company that manufactures BalanceWear. I have joined Cindy in numerous treatment sessions and I am always inspired when I witness the immediate improvement in someone who has spent years struggling to manage daily activities due to poor balance. Its a wonderful experience.

Gibson-Horn acknowledges that each case is different regarding the degree of improvement that can be achieved after being strategically fitted with BalanceWear. Some patients walk nearly normally with BalanceWear, she says. We can see immediately upon application if a patients balance has been corrected. Further, we now know that the improved stability provided by BalanceWear is helpful in increasing confidence, which can lead to improved success in physical therapy often accelerating results.

Balance-Based Torso-Weighting is an assessment and treatment method that results in a BalanceWear custom made, strategically weighted orthotic. BalanceWear is made to the exact specifications for the patients counter-balancing requirements, providing supplementary sensory information to the nervous system, and helping to improve balance and stability in all directions of movement. Clinically, patients with the following conditions have found balance and mobility improvement with BalanceWear - Parkinsons disease, Multiple Sclerosis, stroke, head trauma, brain surgery, osteoporosis, ataxia, Cerebral Palsy and dizziness.

Dr. Gail Widener at Samuel Merritt University in Oakland, California and Dr. Diane Allen at San Francisco State University will present their research at the 64 Annual Academy of Neurology April 26th and at the Consortium Of MS Centers annual conference on June 1, 2012.

For more information on BalanceWear, visit http://www.motiontherapeutics.com. Motion Therapeutics is a provider of therapeutic products designed to improve balance, stability and mobility in many disease states utilizing patented Balance-Based Torso-Weighting (BBTW) technology available in the patented BalanceWear Series mobility products. The companys products are designed to: accelerate the recovery and rehabilitation of adults and children with balance challenges; and, improve the mobility, confidence, and independence of individuals. Visit MotionTherapeutics.com to learn more.

More:
Multiple Sclerosis Patients Find Improvement in Walking with BalanceWear®

Experimental Drug Improves Autism-Like Symptoms in Mice

]ys6{)&5kMQ!y=G2lfR*$F~ uXc{Mlh Mb(}}fc?w0?iv"^L]<9(P6q}UWk{0KU,AaL*-PW{3/zJ]}5Z3C(]w:b`tl{=[5g2A;TL@(t:kO2S,9QC2t~ENL#|235w#VN#&G",#v4s**E0_Eh;ahz*K+0?2 MWa'JE(gC D'2*pg"HR6joC%Vyl3& cH'T&dUh2E1K<82fC.UD`/E]$<>*ix-x 70cW1SGLT6 H#S;wo eOf"rq6xFdb h]rlKB=:Dk4~#LOC `RO P _88x{0# '>km5y!1AtsJh-KfPFW@5Da& |0##F{IOme %WQ}/> / *>PB5H^kJkuV-%y}Y3%#T-CMP.EE 7%6V+{$4MGOItd{h+vk2_|4Bc.(8a.S/l6ez|-vsloUy_rL/_Znt`z*Ls=AjSfvb)7.+tr5.`Wc3T%'"I$T>,sR} n4Qun. "rf ( jp?,^f'`OHAt VK`r,<0@tH t=&a_Z$ow +qONY Q'#4X3o20X'CdF+$@!V4P"Si<8h4Su{{=h{Q{0#>@=RB=XN[HDRoO#k6{ux9'qQ<$06)|r&Z{H_ d$"q_h`NlJ m8s%yBB"5}=A(QoZUQ=i=c E=#o5%Llbz0 2X2p) N7i$y"N,S"A.)]l)>hNg6q=Av_Wc"^9wXtVS}]yqp3@1Gc8[,%&Q(#iuKu $fU*mxCr4PsCZ^(}nC"98Nd|%e%_ofxo4$Vk"I%/ ,q{S|z;zyJ1-}Hv )ECDjfR3oGY5Q@(Q(Yid*Ozw'C)sYe^cqHfS VOd|YOg+Qc4qW:TjfyY6/!jQ[fiT@vs[V{5MUJ>Oh-MXf T.u0_ m1EDE|sa>~yF |-g424Lv8Q[@_8aMFZF<|4M`OZVpEXf`h6`.XC4 Da5 ?[rz8& U$77G6>Y~IDHI`NUtj{T~ez^eqRn=Xy:H9EGFF4>41'V@xtHQ~~G }(G[@^F!QV>M"!-bM~f[|G~k#(wh"C~eoM3.-kbbeDZdeNk&^)?1a(PHA;EQZq?Oa1ZAKL6]F$$'<,o TFzD6$ydXA8 $r'4_] 6!@B 1 BP!;$JpB'e)~h Qbd?%>d9tTj1eR,=fI+Ti4U,`t4T`#ad|iaB|xA]'HZ4EknzC+4(M QQh8)>0,TL@1%^UmT0&kO#@+:_6&CC<#P,T_*UGOC"/$ Oa!4=iOI tgPD]1qF7(ZSb d]CtW9`CAco=knr;m!UtS]umfe_a=}b?;A.Nx<*$QchRR/VRGFdWfk&N^~x}f'MsQqjN-e h3+xLWplSEl3(D))b&O(XEZS-2Cn)TO#+2_fY>*~;_v{7~8 )s)o!%4C*.#5dUk.k:Fl}) :oMUqq8AU(K&0z&KhCbSP'_3CR "lmcwwoc!PTvZ/$O|vdUJ,+y|3{j!=}a+E"93bFwC(!vKcE x<2MU W@ni@-8z+rZ?xk&'B 02(#!~Az|0;re ~ih^/YY/VOP0]N%] I,+F,~YFW$iM9wCR48*uyF)U

Read the rest here:
Experimental Drug Improves Autism-Like Symptoms in Mice

An Autistic's Response: "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher" – Video

25-04-2012 16:38 This is my response to the video "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher and Aide." To learn more check out the link here: My name is Kerry Magro and I was diagnosed with Autism at 4 and feel a great deal of compassion for Stuart and his 10 year old autistic son, Akian and there situation with The Cherry Hill School System. Please sign his petition here to help start a zero tolerance policy for teachers who bully their students: Join the Facebook Page "No More Teacher Bullies" here: Thanks to Stuart so much for making this public and sharing his voice with us! If you want to learn more about how I'm sharing my voice with others please check out my Blog here: my Homepage here: liking my Facebook Fan Page here: or following me on Twitter @kerrymagro Below I'm leaving you the description of what Stuart mentioned under his video description based on the situation with him and his son. For more information about the video please see below along with checking his Homepage here: "My name is Stuart Chaifetz, and my son, Akian, is a ten-year old boy who has Autism. Akian has always been a sweet and non-violent child, and that is why it was so distressing when notes started coming home from his school, Horace Mann Elementary in Cherry Hill, New Jersey, saying that he was having violent outbursts, including him hitting his teacher ...

Continue reading here:
An Autistic's Response: "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher" - Video

An Autistic’s Response: “Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher” – Video

25-04-2012 16:38 This is my response to the video "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher and Aide." To learn more check out the link here: My name is Kerry Magro and I was diagnosed with Autism at 4 and feel a great deal of compassion for Stuart and his 10 year old autistic son, Akian and there situation with The Cherry Hill School System. Please sign his petition here to help start a zero tolerance policy for teachers who bully their students: Join the Facebook Page "No More Teacher Bullies" here: Thanks to Stuart so much for making this public and sharing his voice with us! If you want to learn more about how I'm sharing my voice with others please check out my Blog here: my Homepage here: liking my Facebook Fan Page here: or following me on Twitter @kerrymagro Below I'm leaving you the description of what Stuart mentioned under his video description based on the situation with him and his son. For more information about the video please see below along with checking his Homepage here: "My name is Stuart Chaifetz, and my son, Akian, is a ten-year old boy who has Autism. Akian has always been a sweet and non-violent child, and that is why it was so distressing when notes started coming home from his school, Horace Mann Elementary in Cherry Hill, New Jersey, saying that he was having violent outbursts, including him hitting his teacher ...

Continue reading here:
An Autistic's Response: "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher" - Video

Experimental drug curbs autism symptoms in mice

(CBS News) Autism affects one out of every 88 American children and while there are available treatments for early intervention, there is no cure. A new government-funded study has found an experimental treatment is effective at reversing symptoms of autism in mice.

VIDEO: Service dogs improving lives of autistic children 10 early warning signs of autism Complete coverage: Latest developments in autism

For the study, published in the April 25 issue of Science and Translational Medicine, researchers from the National Institutes of Health bred a strain of mice to display autism-like behaviors. Similar to how children with autism have social deficits and engage in repetitive behaviors, these mice did not interact and communicate with each other and spent an inordinate amount of time engaging in repetitive behavior - in this case self-grooming.

Cue the experimental drug called GRN-529. The drug was designed to inhibit a type of brain cell receptor that receives the neurotransmitter glutamate. Glutamate is typically involved in learning and memory processes and stimulates other areas of the brain and nervous system.

When mice with the autism-like behaviors were injected with the experimental compound, they reduced the frequency of their repetitive self-grooming and spent more time around strange mice, even sniffing them nose to nose. When tested on a different strain of mice, the experimental compound stopped all repetitive jumping behavior.

"These new results in mice support NIMH-funded research in humans to create treatments for the core symptoms of autism," Dr. Thomas R. Insel, director of the National Institute of Mental Health, said in a statement. "While autism has been often considered only as a disability in need of rehabilitation, we can now address autism as a disorder responding to biomedical treatments."

The researchers said although most mouse brain findings often don't translate to humans, the fact that these compounds are already being tested for an overlapping condition strengthens the case for the drug's effectiveness. This class of compounds is currently being studied in patients with the genetic disease Fragile X syndrome, the most common inherited form of intellectual disability. About one third of patients with Fragile X syndrome also meet criteria for autism.

"These inbred strains of mice are similar, behaviorally, to individuals with autism for whom the responsible genetic factors are unknown, which accounts for about three fourths of people with the disorders," noted study author Dr. Jacqueline Crawley of the NIMH. "Given the high costs - monetary and emotional - to families, schools, and health care systems, we are hopeful that this line of studies may help meet the need for medications that treat core symptoms."

Some experts exercised caution with the new findings. In an accompanying editorial in the same journal issue, Baltazar Gomez-Mancilla, executive director of translational medicine neuroscience at Novartis, wrote, "It is too early to speculate as to whether or not autism spectrum disorders can be reversed by small molecules."

Dr. Uta Frith, a professor of cognitive development at University College London, told BBC News that neurotransmitter problems have long been suspected as an origin of autism, "However, it will be a long time until these findings can be translated for human patients. Tampering with the synapse may well result in undesirable side effects," he said.

Read the rest here:
Experimental drug curbs autism symptoms in mice

Experimental drug alleviated autism symptoms in mice

By Deborah Kotz, Globe Staff

While many potential drugs to treat autism are being tested in experimental settings, a new one appears fairly promising -- at least in mice. Researchers from the National Institutes of Mental Health and Pfizer reported Wednesday that an experimental compound, called GRN-529, increased social interactions and lessened repetitive self-grooming behavior in a strain of mice bred to display autism-like behaviors.

The mouse in the video above was interested only in repeatedly cleaning its coat of fur before it was given the drug; after getting the drug, it went to an attached cage to try to engage with a new mouse it had never encountered before.

Our findings suggest a strategy for developing a single treatment that could target multiple diagnostic symptoms, Jacqueline Crawley, a researcher at the mental health institute, said in a statement. Many cases of autism are caused by mutations in genes that control an ongoing process -- the formation and maturation of synapses, the connections between neurons. If defects in these connections are not hard-wired, the core symptoms of autism may be treatable with medications.

The study, published in the journal Science Translational Medicine, is one of several to test a class of drugs that inhibit a cell receptor called mGluR5, thats known to play a role in Fragile X, an autistic-like syndrome. Clinical trials to test these drugs on Fragile X patients are already underway.

Together, the new and previous findings suggest that clinical trials should be initiated to test the effects of mGluR5 inhibitors in autism patients, wrote Baltazar Gomez-Mancilla, a researcher for the drug company Novartis, in a paper that accompanied the study. But whether the agent would work in older children and adults with autism remains questionable at best. It could be, added Gomez-Mancilla, that the limited plasticity of the adult brain mandates intervention at earlier ages, ideally at the time of diagnosis.

Read more here:
Experimental drug alleviated autism symptoms in mice

Prospect of 'autism drug' raised

25 April 2012 Last updated at 14:00 ET By James Gallagher Health and science reporter, BBC News

The prospect of a drug to treat autism has been raised after symptoms of the condition were reduced in experiments on mice that were performed by the US National Institutes of Health.

There is no cure for the condition.

The results published in Science Translational Medicine showed increased social skills and less repetitive behaviour in animals taking a drug.

However, treatments which work in mice frequently fail in humans and potential medication would be years away.

Autism spectrum disorder is thought to affect around 1% of children. It ranges from mild to severe and symptoms include social problems, delayed language and repetitive movements such as hand tapping.

Autism is mainly treated with specialist education, speech and behavioural therapies.

Researchers at the National Institutes of Health said autism had been thought to be untreatable by drugs. The theory was that any problems would be "hardwired" into the brain.

It will be a long time until these findings can be translated for human patients

However, they said there was evidence that in some cases autism could be down to the way cells in the brain communicate with each other at synapses, the gaps between individual brain cells.

Read the original post:
Prospect of 'autism drug' raised

Prospect of ‘autism drug’ raised

25 April 2012 Last updated at 14:00 ET By James Gallagher Health and science reporter, BBC News

The prospect of a drug to treat autism has been raised after symptoms of the condition were reduced in experiments on mice that were performed by the US National Institutes of Health.

There is no cure for the condition.

The results published in Science Translational Medicine showed increased social skills and less repetitive behaviour in animals taking a drug.

However, treatments which work in mice frequently fail in humans and potential medication would be years away.

Autism spectrum disorder is thought to affect around 1% of children. It ranges from mild to severe and symptoms include social problems, delayed language and repetitive movements such as hand tapping.

Autism is mainly treated with specialist education, speech and behavioural therapies.

Researchers at the National Institutes of Health said autism had been thought to be untreatable by drugs. The theory was that any problems would be "hardwired" into the brain.

It will be a long time until these findings can be translated for human patients

However, they said there was evidence that in some cases autism could be down to the way cells in the brain communicate with each other at synapses, the gaps between individual brain cells.

Read the original post:
Prospect of 'autism drug' raised